Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored the potential implications of the phase-out of cookies for the broader advertising industry.
In his video interview with Pharmaceutical Executive, Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored the challenges and opportunities in healthcare advertising, particularly in the context of increasing data privacy regulations and the decline of third-party cookies. The discussion highlighted the importance of leveraging real-world data (RWD) to gain valuable insights into patient behavior and preferences. RWD, when combined with advanced analytics and privacy-compliant targeting techniques, enables more effective and targeted advertising campaigns. The conversation also touched on the potential impact of cookie deprecation on the broader advertising industry and the need for advertisers to adapt to a more privacy-centric approach.
it's a tricky question. I mean that the headline is that media efficiency may experience a decline over the next few years. If you know, the majority of you know, audio of media that's being bought is no longer addressable through some form of segmentation. But I say May because, you know, there are a wide variety of media channels that contribute to the overall spend in our space. And one of the major countervailing forces there has been a space that has never been that accurate, which is TV.
This is a big year for television in that, I believe, for the first time this year, the number of CTV connected households is set to surpass linear which means you no longer have to buy on extremely broad demos against, say, you know, a time of day in a particular show, you can buy more at the addressable household level. That is a massive shift, sea change, I should say, in in how efficient you can be with the deployment of dollars in the television space. So, while you know digital, and by digital, I mostly mean mobile. At this point, may go down in efficiency. You could see an increase at the same time of addressability through connected television. So, I don't want to say it's all negative, but we really have to look to, you know, how ongoing third party cookie deprecation is carried out, and whether or not these new alternative addressability solutions really grow and become the backbone of segmentation in digital advertising.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
2 Commerce Drive
Cranbury, NJ 08512